Well, it is. DCVax-L going from stup to fully annotated drug in the Canadian DrugBank, process started March 3rd. is a clear indication that we are in a rolling review through either ORBIS/ILAP and thus ... multiple RAs involved.
The function of DCs is on full display in this trial data. The idea that regulators are too ignorant to understand this is ludicrous. The idea that you might be attempting to dissuade some from believing that “the process” is being shown to be so outdated as to be harmful to patients seems rather obvious. Besides this, juries aren’t going to be pleased that some companies and those working for them have profited by blood money earnings. Best wishes.
Market Data 
Markets 
AI
